Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Detailed price information for Bristol-Myers Squibb Company (BMY-N) from The Globe and Mail including charting and trades.

In an open letter, 22 experts who designed and ran Replimmune’s Phase III IGNYTE trial answered the FDA’s issues, as outlined ...

Second quarter earnings season is in full swing, and the results have been largely positive so far, with more positive ...

Pfizer raised its full-year profit forecast on Tuesday while reporting second-quarter results that topped Wall Street ...

Bristol Myers Squibb (BMS) and Bain Capital have created an independent biopharmaceutical company to develop immunology ...

Pfizer said the new forecast includes a one-time charge of 20 cents per share related to its recent licensing deal with China ...

Princeton: Bristol Myers Squibb has announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental ...

Why it matters: In addition to ongoing clinical trial progress for BNT327, BioNTech was active on the business development ...

These three dividend payers have an average yield of 4.5%. David Harrell: Hi, I’m David Harrell, editor of the Morningstar ...

Bristol Myers Squibb offers a 5.6% dividend yield, strong cash flow, and AI-driven growth potential. See why I see this as a ...

During a live event, Hans Lee, MD, and participants discussed potential approaches to modifying frontline multiple myeloma ...